Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to $679000.0.

  • ImmunoTech's Accumulated Expenses fell 3283.88% to $679000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $679000.0, marking a year-over-year decrease of 3283.88%. This contributed to the annual value of $606000.0 for FY2024, which is 6948.64% down from last year.
  • According to the latest figures from Q3 2025, ImmunoTech's Accumulated Expenses is $679000.0, which was down 3283.88% from $573000.0 recorded in Q2 2025.
  • ImmunoTech's Accumulated Expenses' 5-year high stood at $2.0 million during Q4 2023, with a 5-year trough of $528000.0 in Q2 2023.
  • For the 3-year period, ImmunoTech's Accumulated Expenses averaged around $998800.0, with its median value being $739000.0 (2024).
  • Data for ImmunoTech's Accumulated Expenses shows a peak YoY increase of 5132.58% (in 2024) and a maximum YoY decrease of 6948.64% (in 2024) over the last 5 years.
  • Over the past 3 years, ImmunoTech's Accumulated Expenses (Quarter) stood at $2.0 million in 2023, then tumbled by 69.49% to $606000.0 in 2024, then grew by 12.05% to $679000.0 in 2025.
  • Its last three reported values are $679000.0 in Q3 2025, $573000.0 for Q2 2025, and $639000.0 during Q1 2025.